New research shows that patients undergoing total joint replacement are younger now than they were in 2000. According to a review from the National Inpatient Sample (NIS) database, the average patient undergoing a total hip replacement (THR) in 2014 was 64.9 years, while the average patient in 2000 was 66.3 years. In parallel, the average patient undergoing a total knee replacement (TKR) was 65.9 in 2014, and 68.0 in 2000.
Dr. Matthew Sloan, lead researcher and orthopaedic resident at the University of Pennsylvania in Philadelphia, tells Reuters Health by email: “These differences may not seem like much, but an average decrease of two years in a pool of 1 million people is a significant difference. It’s also a meaningful difference when you take into account the fact that these total joint replacements have a finite lifespan.”
Dr. Sloan further explains: “The technology for total hip and knee replacements continues to improve. However, at some point, the implant wears out. We believe modern implants without any unforeseen complications should last 20 years or more. The problem with an increasingly younger group of patients having these procedures, it becomes more likely that the implant will wear out during their lifetime. When this happens, a second surgery is required to revise the joint replacement. These procedures are not as successful as the initial surgeries, they are bigger operations, they take longer, and now the patient is 20 years older and not as strong as they were when they had the initial procedure.”
Because a second surgery is riskier and prone to complications like early failure or infection, the goal is to wait as long as possible so that a patient will undergo one surgery in their life. Other findings presented at the American Society of Orthopaedic Surgeon’s annual meeting include: Continue reading
Canadian Obesity Network publishes first-ever Report Card On Access to Obesity Treatment For Adults in Canada 2017
A paradigm shift in the prevention and treatment of obesity.
The report is a shift away from considering obesity to be merely the result of poor lifestyle choices toward a socio-ecological model of health that carries with it an obligation to our health systems and society to prevent and treat it as we do other chronic diseases.
Understanding your Body Mass Index (BMI)
Health Canada’s Canadian Guidelines for Body Weight Classification in Adults uses the Body Mass Index (BMI) to determine if someone is overweight. You can calculate your BMI using the formula below or online here:
BMI = weight (kg)/height (m)2
Health Canada’s Health Risk Classification According to Body Mass Index (BMI) table shows the correlation between your BMI score and your risk of developing health problems, such as type 2 diabetes, high blood pressure, heart disease, stroke, arthritis and cancer. Please note other factors may influence your BMI. You should consult your family physician if you are concerned about being overweight.
Image courtesy of yodiyim at FreeDigitalPhotos.net
According to a study published in Osteoarthritis and Cartilage, the rate of osteoarthritis (OA) is increasing and Canada’s aging population and rising rate of obesity is to blame. Osteoarthritis is a leading cause of chronic pain and loss of mobility in Canada and is associated with reduced productivity and increased burden on the health care system.
Statistics Canada reports that almost two-thirds of Canadian adults and 23% of children are overweight or obese. “These compelling demographic trends will increase the burden of OA and the associated disability among the working age population will become substantial in the coming years,” Behram Sharif, research team lead and an Alberta Bone and Joint Health Institute post-doctoral fellow based at the University of Calgary, said. Continue reading
A recent study published in the journal Arthritis & Rheumatology concluded that disease-modifying anti rheumatic drugs (DMARDs) may influence rheumatoid arthritis (RA) patients’ weight. The study looked at four DMARDs, including methotrexate, leflunomide, prednisone and tutor necrosis factor inhibitors (TNFis).
Researcher Joshua F. Baker and his team at the Philadelphia VA Medical Centre in Pennsylvania assessed how primary RA therapies influence changes in body mass index (BMI). A low BMI is one of the adverse long-term outcome in RA and disease-related weight loss may be the result of RA symptoms or treatment therapy.
The team used three large administrative databases to identify 32,859 RA patients who received treatment with methotrexate, leflunomide, prednisone and TNFis. Researchers also assessed independent factors that may affect the study outcome, including the patient’s age, sex, race, BMI, seropositivity* for anticyclic citrullinated peptides (CCP), diabetes, current smoking habits, comorbidities, C-reactive protein (CRP) levels, interstitial or other lung disease, malignancies, history of myocardial infarction, chronic kidney disease, and other factors.
Here are the findings from the study: Continue reading